Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-10 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation
Checked against the public recordLast updated Jul 14, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Brigham and Women's Hospital
- Interventions being studied
- Radiation: Stereotactic Radiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants must have a biopsy-proven tumor consistent with small cell lung cancer and intracranial lesions radiographically consistent with or pathologically proven to be brain metastases. Patients who have undergone prior systemic therapy are eligible. Patients who have undergone resection of one or more brain metastases but who have not yet started adjuvant radiotherapy are eligible for the study. * 1-10 definitive intracranial lesions must be present on MRI of the brain. * Age \>=18 years at diagnosis of brain metastases. Exclusion Criteria: * Participants who have undergone prior radiation for brain metastases. * Participants who have received prophylactic cranial radiation for prevention of brain metastases * Participants who cannot receive gadolinium * Participants with stage IV-V chronic kidney disease or end stage renal disease * Participants with widespread, definitive leptomeningeal disease * Participants with a maximum tumor diameter exceeding 5 cm (if not resected) * Participants with \>6 definitive lesions consistent with brain metastases * Participants with inadequate mental capacity to complete quality of life questionnaires
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Dana Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 14, 2026. Always confirm current availability with the study team.